Net Income

Celebrating 50 years, the largest US ethnic credit union awarded a record $700K to 602 students, reinforcing its deep commitment to the Polish-American community.

As Jones Soda prepares for the Planet MicroCap conference, its impressive financial rebound and bold diversification strategy take center stage for investors.

As SpaceX makes its historic market debut, GraniteShares launches leveraged ETFs, offering traders a high-stakes way to bet on the volatile space pioneer.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?

FCPT's latest acquisition seems minor, but it reveals a powerful strategy for navigating economic uncertainty by targeting essential, service-based real estate.

Tokyo-based CTW, a leader in web-based anime games, is pitching to US microcap funds. What's the strategy behind this cross-border play for capital?

AM Best's 'a-' rating on Ameriprise's new notes isn't just a grade; it's a testament to strategic foresight and a beacon for investors.

Hyperscale Data is deploying humanoid robots in its Michigan data center, a high-stakes bet to teach AI about the real world amid major financial pressures.

American Outdoor Brands faces a key test on June 25. With mixed results and a shifting market, can its innovation strategy deliver on investor hopes?

With its new 'Edge' plans, the nation's largest customer-owned insurer is using digital tools and psychological 'nudges' to guide patient choices.

Northern 2 VCT holds dividends steady despite an NAV dip, celebrating a major IPO while facing new principal risks from AI and UK tax policy changes.

Despite a dip in NAV, Northern Venture Trust raises £30M and maintains dividends, bracing for the impact of a major VCT tax relief cut on UK startups.

AIFU, a Chinese fintech firm on the brink, plans to acquire a waste-tech AI company. Is this a visionary leap into green industry or a desperate gamble?

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

RenX just wiped $7M of debt in a savvy insider deal. It’s more than a balance sheet fix—it’s a calculated bet on a tech-driven, sustainable future.

A key deal locking in generic drug prices is extended, promising billions in savings for healthcare and providing crucial stability for a fragile industry.

A Nasdaq non-compliance notice threatens BIO-key's listing, revealing a pattern of reporting delays that casts a shadow over its operational wins.

Aethlon Medical is advancing a device to filter pathogens from the bloodstream, viewing it as a firewall for the body's internal communication network.

The marine tech firm posted another quarter of positive Adjusted EBITDA, but a sharp drop in orders reveals deep industry headwinds. Is its stable after-market business enough?

As Kewaunee Scientific preps its year-end report, all eyes are on whether its bold Nu Aire acquisition can translate revenue gains into long-term profit.